Johnson & Johnson’s Tecvayli plus Darzalex Faspro improves overall survival in new analyses of the Phase III MajesTEC-3 in multiple myeloma, while Rafael Holdings’ Trappsol Cyclo missed its primary endpoint in a Phase III Niemann-Pick type C trial.
Johnson & Johnson’s Tecvayli plus Darzalex Faspro improves overall survival in new analyses of the Phase III MajesTEC-3 in multiple myeloma, while Rafael Holdings’ Trappsol Cyclo missed its primary endpoint in a Phase III Niemann-Pick type C trial.